Traws Pharma
TRAW
23 hedge funds and large institutions have $18.1M invested in Traws Pharma in 2018 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 1 closing their positions.
1,300% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 1
205% more capital invested
Capital invested by funds: $5.92M → $18.1M (+$12.2M)
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
130% more funds holding
Funds holding: 10 → 23 (+13)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more ownership
Funds ownership: 0.01% → 0.01% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$6.11M |
| 2 |
TCP
Tyndall Capital Partners
New York
|
+$5.24M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$3.87M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.86M |
| 5 |
KC
Kepos Capital
New York
|
+$1.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$174K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$14.5K |
| 3 |
Millennium Management
New York
|
-$12K |
| 4 |
HFM
Hartford Financial Management
Hartford,
Connecticut
|
-$1K |
TRAW Hedge Fund Activity: Q2 2018 in Review
23 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q2 2018, worth a combined $18.1M — up 205% from $5.92M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new TRAW positions and 1 closed out — a net gain of 13 holders — while 5 added to existing stakes and 2 trimmed.
The largest buyer was 683 Capital Management, adding an estimated $6.11M. The largest seller was Sabby Management, cutting an estimated $174K.
- 23 institutional investors held Traws Pharma (TRAW) as of Q2 2018, up from 10 in Q1 2018.
- Funds reported $18.1M of Traws Pharma stock for Q2 2018, up 205% quarter-over-quarter.
- 14 funds opened new Traws Pharma positions in Q2 2018 and 1 closed out, a net change of +13 holders.
- The largest Traws Pharma buyer in Q2 2018 was 683 Capital Management, an estimated $6.11M added.
- The largest Traws Pharma seller in Q2 2018 was Sabby Management, an estimated $174K sold.
Based on aggregated 13F filings for Q2 2018.